RUI-products
Official Sponsor
Dopamine Agonist? I thought Prami controlled prolactin in research subjects? That’s right it does, however it does so by acting as a dopamine agonist. Dopamine and Prolactin have an inversely proportional relationship. Meaning if Dopamine is high – Prolactin will be low. Use of a Dopamine agonist has proven the preferred method in several studies and in practical research applications to lower Prolactin levels. So what makes Prami the BEST?
Well first let’s look at Prolactin and what its effects are in research subjects. Prolactin is a hormone released by the pituitary gland. It induces lactation and combined with excess estrogen will encourage breast tissue growth (gyno in male research subjects). It is also responsible for the refractory period, the time which it takes a make to fully recover after sexual activity to be able to perform the act again. Obviously it plays a key role in sexual function, or dysfunction.
The main reason for use of a dopamine agonist in research subjects is 2 fold. 1- To avoid any breast issues in male research subjects and to avoid sexual dysfunction. The agonist activity on dopamine receptors lowers prolactin levels sufficiently to help with these effects. So what makes Prami the best? Well dopamine agonists act on the d2 and d3 receptors both. Prami, however, in addition to exerting potent effect on d2 receptors has a 7 times higher affinity for the d3 receptor than any other dopamine agonist. Well the d3 receptor is responsible for males’ sexual interest, sexual arousal, and sexual function. Prami will not only lower overall prolactin levels in research subjects, it will agonize the very receptor responsible for playing a key role in male sexual function. It does this 7x more than any other dopamine agonist. Prami crushes sexual dysfunction.
Other benefits of Prami include a neuroprotective effect. Offsetting effects of neurodegenerative diseases (ie parkisons , alzheimers).
It has been shown to elevate mood and stave off depression in research subjects.
Where as bromocriptine and cabergoline have been associated in studies with increased cardiac incidents – this is not the case with Pramipexole. In fact in the very same study it was found that with Pramipexole, “ no such increases were observed for nonergot-derived drugs-Pramipexole.”
Prami also induces a 2 hr increase im GH release im research subjects. A GH increase statistically significant enough to be repeatedly noted and mentioned in several studies as a demonstrated effect.
When administered to research subjects properly, slowly increasing amount administered till desired dose is reached. Prami is an extremely well tolerated research compound which will illicit all the benefits mentioned above. It truly is the best Dopamine Agonist for our research purposes.
Check it out >> Liquid Prami 60mL 1mg/mL
Refs:
*ZAO DUNG LING, HEATHER C. ROBIE, CHONG WAI TONG, and PAUL M. CARVEYNeuropharmacology Research Laboratories, Departments of Pharmacology (Z.D.L., H.C.R., C.W.T., P.M.C.) and Neurological Sciences(Z.D.L., P.M.C.), Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IllinoisAccepted for publication November 11, 1998 This paper is available online at Journal of Pharmacology and Experimental Therapeutics
* http://jpet.aspetjournals.org/content/289/1/202.full.pdf
*Cancer and Sexual Health - John P. Mulhall - Google Books
*Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans.Schilling JC, Adamus WS, Palluk R.Human Pharmacology Centre, Boehringer Ingelheim KG, Germany. PMID: 1350237 [PubMed - indexed for MEDLINE]
* Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.Lemke MR, Brecht HM, Koester J, Reichmann H.Center of Psychiatry and Neurology, Rhine Clinic Bonn, Germany. mr.lemke@lvr.de PMID: 16814808 [PubMed - indexed for MEDLINE]
* Pre-clinical studies of pramipexole: clinical relevance.Hubble JP.Department of Neurology, The Ohio State University Parkinson's Disease Center, Columbus, Ohio 43210, USA. PMID: 11054154 [PubMed - indexed for MEDLINE]
Liquid Prami 60mL 1mg/mL
Well first let’s look at Prolactin and what its effects are in research subjects. Prolactin is a hormone released by the pituitary gland. It induces lactation and combined with excess estrogen will encourage breast tissue growth (gyno in male research subjects). It is also responsible for the refractory period, the time which it takes a make to fully recover after sexual activity to be able to perform the act again. Obviously it plays a key role in sexual function, or dysfunction.
The main reason for use of a dopamine agonist in research subjects is 2 fold. 1- To avoid any breast issues in male research subjects and to avoid sexual dysfunction. The agonist activity on dopamine receptors lowers prolactin levels sufficiently to help with these effects. So what makes Prami the best? Well dopamine agonists act on the d2 and d3 receptors both. Prami, however, in addition to exerting potent effect on d2 receptors has a 7 times higher affinity for the d3 receptor than any other dopamine agonist. Well the d3 receptor is responsible for males’ sexual interest, sexual arousal, and sexual function. Prami will not only lower overall prolactin levels in research subjects, it will agonize the very receptor responsible for playing a key role in male sexual function. It does this 7x more than any other dopamine agonist. Prami crushes sexual dysfunction.
Other benefits of Prami include a neuroprotective effect. Offsetting effects of neurodegenerative diseases (ie parkisons , alzheimers).
It has been shown to elevate mood and stave off depression in research subjects.
Where as bromocriptine and cabergoline have been associated in studies with increased cardiac incidents – this is not the case with Pramipexole. In fact in the very same study it was found that with Pramipexole, “ no such increases were observed for nonergot-derived drugs-Pramipexole.”
Prami also induces a 2 hr increase im GH release im research subjects. A GH increase statistically significant enough to be repeatedly noted and mentioned in several studies as a demonstrated effect.
When administered to research subjects properly, slowly increasing amount administered till desired dose is reached. Prami is an extremely well tolerated research compound which will illicit all the benefits mentioned above. It truly is the best Dopamine Agonist for our research purposes.
Check it out >> Liquid Prami 60mL 1mg/mL
Refs:
*ZAO DUNG LING, HEATHER C. ROBIE, CHONG WAI TONG, and PAUL M. CARVEYNeuropharmacology Research Laboratories, Departments of Pharmacology (Z.D.L., H.C.R., C.W.T., P.M.C.) and Neurological Sciences(Z.D.L., P.M.C.), Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IllinoisAccepted for publication November 11, 1998 This paper is available online at Journal of Pharmacology and Experimental Therapeutics
* http://jpet.aspetjournals.org/content/289/1/202.full.pdf
*Cancer and Sexual Health - John P. Mulhall - Google Books
*Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans.Schilling JC, Adamus WS, Palluk R.Human Pharmacology Centre, Boehringer Ingelheim KG, Germany. PMID: 1350237 [PubMed - indexed for MEDLINE]
* Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.Lemke MR, Brecht HM, Koester J, Reichmann H.Center of Psychiatry and Neurology, Rhine Clinic Bonn, Germany. mr.lemke@lvr.de PMID: 16814808 [PubMed - indexed for MEDLINE]
* Pre-clinical studies of pramipexole: clinical relevance.Hubble JP.Department of Neurology, The Ohio State University Parkinson's Disease Center, Columbus, Ohio 43210, USA. PMID: 11054154 [PubMed - indexed for MEDLINE]
Liquid Prami 60mL 1mg/mL
